PDS Biotechnology
Lars Boesgaard is a seasoned finance executive with extensive experience in various leadership roles within the biotechnology, pharmaceutical, and medical device industries. Currently serving as Chief Financial Officer at PDS Biotechnology since December 2023, Lars previously held CFO positions at AM-Pharma and Columbia Care, and served as Vice President and CFO at Roka Bioscience, where key contributions included an IPO in 2014. Lars also has a background as Vice President of Finance at Insulet Corporation, contributing to the launch of the first tubing-free insulin pump, and as Senior Director of Financial Services at Alexion Pharmaceuticals, where support was provided for the commercialization of a novel product. Earlier career roles include senior finance positions at Nielsen and Novo Nordisk A/S, where Lars managed complex financial operations and reporting. Educational credentials include an MBA from Ivey Business School and a B.Sc. from Copenhagen Business School.
This person is not in any offices
PDS Biotechnology
PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers;PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers.PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.